[{"id":"61ca0b9b-1509-4168-84b0-c850998dc316","acronym":"","url":"https://clinicaltrials.gov/study/NCT06773377","created_at":"2025-02-25T20:23:14.681Z","updated_at":"2025-02-25T20:23:14.681Z","phase":"","brief_title":"Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma","source_id_and_acronym":"NCT06773377","lead_sponsor":"Assiut University","biomarkers":" CD44","pipe":"","alterations":" ","tags":["CD44"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2025","start_date":" 11/01/2025","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-14"},{"id":"61649098-7ef6-4a13-80de-89bda601b206","acronym":"","url":"https://clinicaltrials.gov/study/NCT05916443","created_at":"2023-06-23T13:09:24.855Z","updated_at":"2024-07-02T16:35:42.210Z","phase":"","brief_title":"Dissecting the Biology of Early-onset Colorectal Cancer","source_id_and_acronym":"NCT05916443","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD44 • CD24","pipe":" | ","alterations":" CD33 positive • CD44 expression • CD133 positive","tags":["CD44 • CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD44 expression • CD133 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-07-24"},{"id":"da006f8e-57f2-49ab-a036-89480d8dec57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02448225","created_at":"2021-01-18T11:43:54.285Z","updated_at":"2024-07-02T16:36:02.214Z","phase":"Phase 2","brief_title":"18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules","source_id_and_acronym":"NCT02448225","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" CD44","pipe":" | ","alterations":" CD44 expression","tags":["CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/16/2015","start_date":" 06/16/2015","primary_txt":" Primary completion: 08/02/2021","primary_completion_date":" 08/02/2021","study_txt":" Completion: 10/10/2022","study_completion_date":" 10/10/2022","last_update_posted":"2022-10-19"},{"id":"7258c8df-7d2c-4de0-be2c-bc797c2092c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137653","created_at":"2021-01-18T20:12:26.059Z","updated_at":"2024-07-02T16:36:27.730Z","phase":"Phase 3","brief_title":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","source_id_and_acronym":"NCT04137653","lead_sponsor":"Shengjing Hospital","biomarkers":" ER • PGR • CD44 • CD24","pipe":" | ","alterations":" CD44 expression","tags":["ER • PGR • CD44 • CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 1498","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2021-07-20"},{"id":"0c5c48ba-d7d3-4f6f-bfea-aa634fc92bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137627","created_at":"2021-01-18T20:12:25.557Z","updated_at":"2024-07-02T16:36:52.790Z","phase":"Phase 3","brief_title":"Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT04137627","lead_sponsor":"Indonesia University","biomarkers":" HIF1A • CD44","pipe":" | ","alterations":" CD44 expression • CD133 expression • HIF1A expression","tags":["HIF1A • CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression • CD133 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/04/2017","start_date":" 07/04/2017","primary_txt":" Primary completion: 07/30/2018","primary_completion_date":" 07/30/2018","study_txt":" Completion: 12/18/2018","study_completion_date":" 12/18/2018","last_update_posted":"2019-12-09"},{"id":"2d7d4326-ad74-40fb-982a-d53615a7bd65","acronym":"","url":"https://clinicaltrials.gov/study/NCT01372579","created_at":"2021-01-18T05:37:22.994Z","updated_at":"2025-02-25T13:33:49.852Z","phase":"Phase 2","brief_title":"Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT01372579","lead_sponsor":"Northwestern University","biomarkers":" EGFR • HER-2 • ER • PGR • CD44 • CD24 • ALDH1A1","pipe":" | ","alterations":" HER-2 negative • ER negative","tags":["EGFR • HER-2 • ER • PGR • CD44 • CD24 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Halaven (eribulin mesylate)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2019-06-07"},{"id":"6e11b1bd-5499-4695-84ba-d75b5547d6f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03380299","created_at":"2021-01-18T16:40:52.767Z","updated_at":"2024-07-02T16:37:15.380Z","phase":"","brief_title":"Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis","source_id_and_acronym":"NCT03380299","lead_sponsor":"Assiut University","biomarkers":" CD44 • ITGA4","pipe":"","alterations":" ","tags":["CD44 • ITGA4"],"overall_status":"Unknown status","enrollment":" Enrollment 2","initiation":"Initiation: 07/14/2016","start_date":" 07/14/2016","primary_txt":" Primary completion: 09/14/2018","primary_completion_date":" 09/14/2018","study_txt":" Completion: 12/14/2018","study_completion_date":" 12/14/2018","last_update_posted":"2017-12-21"},{"id":"b2122966-af02-429e-8475-b26ea7a6cadb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01358903","created_at":"2021-01-18T05:33:37.396Z","updated_at":"2024-07-02T16:37:27.969Z","phase":"Phase 1","brief_title":"A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors","source_id_and_acronym":"NCT01358903","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD44","pipe":" | ","alterations":" CD44 expression","tags":["CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2016-11-02"}]